Cargando…
Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials
Telmisartan is indicated for the prevention of cardiovascular events in high-risk patients, based on comparable efficacy to the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET(®)) trial. Howeve...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262485/ https://www.ncbi.nlm.nih.gov/pubmed/22272064 http://dx.doi.org/10.2147/PPA.S27939 |